



September 16, 2025

Company Name	EUCALIA Inc.
Representative	Hideo Misawa
Securities code	286A; Tokyo Stock Exchange Growth Section
Contact	Kazunari Ogawa, Executive Officer, Business Strategy Headquarters General Manager
Phone	+81-3-5501-2271

Notice Regarding Partnership Agreement with Social Medical Corporation HAKUYUKAI

EUCALIA Inc. (Head Office: Chiyoda-ku, Tokyo, President and Representative Director: Hideo Misawa, "EUCALIA") has resolved at its Board of Directors meeting held on September 16, 2025, to conclude a partnership agreement with Social Medical Corporation HAKUYUKAI (Head Office: Akabira-shi, Hokkaido, President: Nobuyuki Takahashi, "HAKUYUKAI"), which operates Hiragishi Hospital (Akabira-shi, Hokkaido) and Kitanomine Hospital (Furano-shi, Hokkaido). As a result, the number of hospitals partnering with EUCALIA has increased by two, with the addition of Hiragishi Hospital and Kitanomine Hospital, bringing the total to 30 hospitals.

1. Reason for the Agreement

In Japan's super-aged society, hospitals, the core providers of community healthcare, are facing increasingly severe management challenges, such as chronic shortages of human resources. Small and medium-sized hospitals, in particular, are burdened with issues such as persistent deficits and a lack of successors, threatening the sustainability of systems that deliver essential medical services to local communities.

EUCALIA has set forth the vision of "Industrialization of Healthcare" and the mission of "Realize the Ideal form of Medical and Nursingcare through Transformation." To this end, the company provides not only consulting but also a broad range of services, including fundraising, procurement, regional collaboration, hospital reconstruction, and digital transformation/data utilization, in order to support hospitals operating under difficult management conditions. These initiatives aim to realize a "good for all three sides (Sanpō Yoshi)" worldview: "stabilizing the management of hospitals and nursing care facilities," improving the job satisfaction and income of healthcare workers," and "improving well-being of patients and those requiring care."

HAKUYUKAI, meanwhile, has long contributed to community healthcare through the provision of psychiatric care services, based in Akabira-shi, Hokkaido.

The conclusion of this agreement will support the sustainable operation of HAKUYUKAI, a community-based social medical corporation, and is positioned as an initiative that contributes to the realization of EUCALIA's vision and mission.

2. Details of the Agreement

Through the conclusion of this agreement, EUCALIA will provide HAKUYUKAI with its expertise in hospital management accumulated over many years, offering management and operational support. In addition, by leveraging EUCALIA's extensive nationwide network, the company will support HAKUYUKAI in becoming a model of optimal hospital management in line with the government's Regional Healthcare Vision.

3. Overview of the Counterparty to the Agreement (HAKUYUKAI)

(1)	Name	Social Medical Corporation HAKUYUKAI
(2)	Location	2-1, Hiragishishinko-cho, Akabira-shi, Hokkaido, Japan
(3)	Job Title and Name of Representatives	Nobuyuki Takahashi, Chairman
(4)	Description of Business	Hiragishi Hospital (Akabira-shi) Kitanomine Hospital (Furano-shi) HAKUYUKAI Takikawa Mental Clinic (Takikawa-shi) Hakujuen Health services facility for the aged (Akabira-shi) Hakuyuso Daily life care in communal living for elderly with dementia (Akabira-shi)
	Specialties	Psychiatry, Internal Medicine, Neurology, others
	Bed Capacity	Hiragishi Hospital: 366 beds Kitanomine Hospital: 170 beds
(5)	Date of Establishment	March, 1963

4. Schedule for the Agreement

(1)	Date of Resolution at the Board of Directors Meeting	September 16, 2025
(2)	Date of Conclusion of the Agreement	September 16, 2025

5. Future Outlook

The impact of this alliance on the EUCALIA's business results for the current fiscal year is expected to be minimal. However, in the medium-long term, we believe it will contribute

to the enhancement of our business performance and corporate value. Should any matters requiring disclosure arise in the future, we will promptly announce any material impact on our financial results.

End